Martien van Osch, MSc
Martien is a founding partner at Forbion Capital Partners.
Martien is Managing Partner and splits his time between operational activities of the Firm and spearheading the medical device related activities at Forbion. He currently actively contributes to the boards of Mitralign and Autonomic Technologies.
He was responsible for the exits of PneumRx, sold to BTG in 2015, Circulite, sold to Heartware in 2013 and Pathway, sold to Bayer Medrad in 2011, Impella, sold to Abiomed, Inc. in 2005 and Flowmedica, Inc., sold to Angiodynamics in 2009. His biopharma experience in the life sciences industry encompasses prior non-executive board positions at Santaris, sold to Roche in ’14 and Acadia (IPO on Nasdaq in 2004).
Before co-founding Forbion, Martien was an Investment Director at ABN AMRO Capital Life Sciences. Before joining in 2000 the newly formed life sciences team, he held other positions in ABN AMRO Capital and in ABN AMRO Group Planning and Control (HQ Amsterdam).
Martien has a degree in Econometrics from the Rijksuniversiteit Groningen.